← Back to patent-cliff list
维格列汀/盐酸二甲双胍
Tier C — Watch / tradeVildagliptin/Metformin Hydrochloride
诺华制药
Originator
2007
First approval
-
Expiry (public)
$0.38B ▲
Peak sales
化学药
Type
Targets：DPP4、PRKAB1
Brand：宜合瑞、Eucreas、Galvusmet、Zomarist、Icandra、EquMet
Indications (approved)：二型糖尿病
Regional status
US
无进展
2006-09-01
EU
批准上市
2007-11-14
China
批准上市
2014-12-09
Japan
批准上市
2015-09-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vildagliptin/Metformin Hydrochloride?
Approved indications include: 二型糖尿病.
When does the Vildagliptin/Metformin Hydrochloride patent expire?
No public expiry year is available for Vildagliptin/Metformin Hydrochloride yet; this page updates once verified.
How do I get a quote for Vildagliptin/Metformin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24